Carl F. Warfvinge
Lund, M, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Patient Survival and Its Relation to Tumor Absorbed Dose in [177Lu]Lu-DOTATATE Therapy of Neuroendocrine Tumors.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 07, 2025
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 16, 2023
Long-term survival of metastatic small intestine neuroendocrine tumors: a meta-analysis.
Journal: Endocrine-related cancer
Published: December 09, 2021
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients.
Journal: European journal of nuclear medicine and molecular imaging
Published: October 13, 2021
Effect of primary tumour resection without curative intent in patients with metastatic neuroendocrine tumours of the small intestine and right colon: meta-analysis.
Journal: The British journal of surgery
Published: June 02, 2021
Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177Lu-DOTATATE.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: February 05, 2021
The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma.
Journal: Oncotarget
Published: February 24, 2017
The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment.
Journal: PloS one
Published: January 18, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026